# CD69

## Overview
CD69 is a gene that encodes a type II transmembrane glycoprotein, which is a member of the C-type lectin superfamily. The CD69 protein is expressed on the surface of various hematopoietic cells, including T cells, B cells, natural killer (NK) cells, monocytes, neutrophils, and platelets, and is one of the earliest markers of lymphocyte activation (Natarajan2000Crystal; Testi1994The). Structurally, CD69 forms a disulfide-linked homodimer, with each subunit containing an extracellular C-type lectin-like domain (CTLD) (Natarajan2000Crystal; Llera2001Crystal). Functionally, CD69 is involved in regulating immune responses through its role in intracellular signaling pathways that lead to calcium influx, cytokine production, and cell proliferation (Marzio1999CD69). The protein also interacts with galectin-1, influencing T cell differentiation and immune homeostasis (de2014The). CD69's expression and function have significant implications in autoimmune diseases, inflammatory conditions, and cancer, making it a potential therapeutic target (Hu2022CD69; Gorabi2020The).

## Structure
The CD69 protein is a type II transmembrane glycoprotein and a member of the C-type lectin superfamily. It is expressed as a disulfide-linked homodimer on the cell surface, with each subunit comprising a single extracellular C-type lectin-like domain (CTLD) (Natarajan2000Crystal; Llera2001Crystal). The primary structure of CD69 includes a 40-residue intracellular domain, a 21-residue transmembrane region, and an extracellular portion with a 20-residue neck and a CTLD of 118 amino acids (Llera2001Crystal).

The secondary structure of CD69 features two alpha-helices and several beta-strands forming antiparallel beta-sheets, similar to other CTLDs (Natarajan2000Crystal; Llera2001Crystal). The tertiary structure is characterized by a conserved CTLD fold, with a hydrophobic core surrounded by polar interactions (Llera2001Crystal). CD69 lacks the typical Ca2+ binding sites found in true C-type lectins, suggesting a different mode of ligand interaction (Natarajan2000Crystal; Llera2001Crystal).

The quaternary structure involves noncovalent dimerization, stabilized by intermolecular hydrogen bonds and hydrophobic interactions, with an intermolecular beta-sheet formed through antiparallel pairing of N-terminal beta strands (Llera2001Crystal). CD69 undergoes post-translational modifications, including glycosylation, which contributes to its structural complexity (Gerosa1991Structural).

## Function
The CD69 molecule is a type II transmembrane glycoprotein expressed on various hematopoietic cells, including T cells, B cells, NK cells, monocytes, neutrophils, and platelets. It is one of the earliest markers to appear following lymphocyte activation and plays a significant role in regulating immune responses (Natarajan2000Crystal; Testi1994The). CD69 is involved in intracellular signaling pathways, leading to calcium influx, cytokine production, and cell proliferation. In T cells, CD69 crosslinking induces cytokine gene expression and proliferation of CD4+ and CD8+ T cells, as well as thymocytes (Marzio1999CD69). 

In neutrophils, CD69 is involved in the regulation of lysozyme release and granule exocytosis, mediated through calcium-dependent mechanisms (Gavioli1992CD69). The molecule also plays a role in apoptosis, as its crosslinking can induce apoptosis in monocytes and eosinophils, potentially serving as a mechanism to remove activated cells and prevent the release of toxic products (Marzio1999CD69). 

CD69's interaction with galectin-1 (Gal-1) influences T cell differentiation, particularly affecting Th17 cell polarization, which is crucial for modulating immune responses and maintaining immune homeostasis (de2014The).

## Clinical Significance
Alterations in CD69 expression are implicated in various autoimmune diseases and inflammatory conditions. In rheumatoid arthritis (RA), CD69 is overexpressed in T-cells from inflamed regions, which induces macrophages to secrete TNF-α, exacerbating the disease. CD69-null mice exhibit reduced arthritis severity, highlighting its role in neutrophil function and cytokine production (Gorabi2020The). In systemic lupus erythematosus (SLE), CD69-positive T-cells are continuously activated, affecting cytokine production, while CD69-negative T-cells produce higher levels of IL-2, IL-3, and IL-4 (Gorabi2020The).

In autoimmune thyroid disorders (AITD) and periodontal disease, CD69-positive regulatory T-cells (Tregs) are present but have reduced inhibitory action, suggesting impaired function (Gorabi2020The). CD69 also plays a role in tumor immune escape, as seen in mouse models of liver cancer, melanoma, and lung cancer, where CD69+ Tregs contribute significantly to the T-cell population in tumor environments (Gorabi2020The).

In the context of cancer, CD69 expression correlates with immune cell infiltration and immune checkpoints in various tumors, suggesting its potential as a biomarker for predicting responses to PD-1/PD-L1 blockade cancer immunotherapy (Hu2022CD69). These findings underscore the clinical significance of CD69 in modulating immune responses and its potential as a therapeutic target.

## Interactions
CD69, a type II transmembrane protein, engages in several specific interactions with other proteins, influencing immune cell signaling and function. One notable interaction is with galectin-1 (Gal-1), a protein that acts as a ligand for CD69. This interaction is direct, specific, and carbohydrate-dependent, as demonstrated by surface plasmon resonance and anti-CD69 blocking analyses. Galectin-1 is expressed on the cell surface of activated T and B cells, macrophages, and tolerogenic dendritic cells (DCs). The CD69-Gal-1 interaction negatively affects Th17 cell differentiation, suggesting a regulatory role in immune responses (de2014The).

CD69 also associates with the Jak/Stat signaling pathway, particularly with Jak3, Stat1, Stat5, and Jak2 proteins. This interaction was confirmed through pulldown assays and immunoprecipitation assays in both human and mouse T-cell blasts. The interaction with Jak3/Stat5 is crucial for regulating Th17 cell differentiation, as CD69 negatively regulates this process through its association with these proteins (Martín2010CD69).

Structurally, CD69 forms a disulfide-linked homodimer at the cell surface, stabilized by an interchain disulfide bond. The dimer interface includes both hydrogen bonds and hydrophobic interactions, which are essential for its function (Natarajan2000Crystal).


## References


[1. (Gorabi2020The) Armita Mahdavi Gorabi, Saeideh Hajighasemi, Nasim Kiaie, Seyed Mohammad Gheibi Hayat, Tannaz Jamialahmadi, Thomas P. Johnston, and Amirhossein Sahebkar. The pivotal role of cd69 in autoimmunity. Journal of Autoimmunity, 111:102453, July 2020. URL: http://dx.doi.org/10.1016/j.jaut.2020.102453, doi:10.1016/j.jaut.2020.102453. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jaut.2020.102453)

[2. (de2014The) Hortensia de la Fuente, Aranzazu Cruz-Adalia, Gloria Martinez del Hoyo, Danay Cibrián-Vera, Pedro Bonay, Daniel Pérez-Hernández, Jesús Vázquez, Pilar Navarro, Ricardo Gutierrez-Gallego, Marta Ramirez-Huesca, Pilar Martín, and Francisco Sánchez-Madrid. The leukocyte activation receptor cd69 controls t cell differentiation through its interaction with galectin-1. Molecular and Cellular Biology, 34(13):2479–2487, July 2014. URL: http://dx.doi.org/10.1128/mcb.00348-14, doi:10.1128/mcb.00348-14. This article has 71 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00348-14)

[3. (Testi1994The) Roberto Testi, Daniele D’Ambrosio, Ruggero De Maria, and Angela Santoni. The cd69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunology Today, 15(10):479–483, October 1994. URL: http://dx.doi.org/10.1016/0167-5699(94)90193-7, doi:10.1016/0167-5699(94)90193-7. This article has 330 citations.](https://doi.org/10.1016/0167-5699(94)90193-7)

[4. (Hu2022CD69) Zhang-Wei Hu, Wei Sun, Yi-Hui Wen, Ren-Qiang Ma, Lin Chen, Wen-Qing Chen, Wen-Bin Lei, and Wei-Ping Wen. Cd69 and sbk1 as potential predictors of responses to pd-1/pd-l1 blockade cancer immunotherapy in lung cancer and melanoma. Frontiers in Immunology, August 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.952059, doi:10.3389/fimmu.2022.952059. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.952059)

[5. (Gavioli1992CD69) Riccardo Gavioli, Angela Risso, Daniela Smilovich, Isabella Baldissarro, M.Cristina Capra, Antonio Bargellesi, and M.Elisabetta Cosulich. Cd69 molecule in human neutrophils: its expression and role in signal-transducing mechanisms. Cellular Immunology, 142(1):186–196, June 1992. URL: http://dx.doi.org/10.1016/0008-8749(92)90279-x, doi:10.1016/0008-8749(92)90279-x. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0008-8749(92)90279-x)

[6. (Martín2010CD69) Pilar Martín, Manuel Gómez, Amalia Lamana, Arantxa Cruz-Adalia, Marta Ramírez-Huesca, María Ángeles Ursa, María Yáñez-Mo, and Francisco Sánchez-Madrid. Cd69 association with jak3/stat5 proteins regulates th17 cell differentiation. Molecular and Cellular Biology, 30(20):4877–4889, October 2010. URL: http://dx.doi.org/10.1128/mcb.00456-10, doi:10.1128/mcb.00456-10. This article has 102 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00456-10)

[7. (Llera2001Crystal) Andrea S. Llera, Fernando Viedma, Francisco Sánchez-Madrid, and José Tormo. Crystal structure of the c-type lectin-like domain from the human hematopoietic cell receptor cd69. Journal of Biological Chemistry, 276(10):7312–7319, March 2001. URL: http://dx.doi.org/10.1074/jbc.M008573200, doi:10.1074/jbc.m008573200. This article has 107 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M008573200)

[8. (Natarajan2000Crystal) Kannan Natarajan, Mark W. Sawicki, David H. Margulies, and Roy A. Mariuzza. Crystal structure of human cd69: a c-type lectin-like activation marker of hematopoietic cells,. Biochemistry, 39(48):14779–14786, November 2000. URL: http://dx.doi.org/10.1021/bi0018180, doi:10.1021/bi0018180. This article has 59 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi0018180)

[9. (Marzio1999CD69) R. Marzio, J. Mauël, and S. Betz-Corradin. Cd69 and regulatiof the immune function. Immunopharmacology and Immunotoxicology, 21(3):565–582, January 1999. URL: http://dx.doi.org/10.3109/08923979909007126, doi:10.3109/08923979909007126. This article has 166 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/08923979909007126)

[10. (Gerosa1991Structural) Franca Gerosa, Marina Tommasi, Maria Scardoni, Roberto S. Accolla, Tullio Pozzan, Massimo Libonati, Giuseppe Tridente, and Giuseppe Carra. Structural analysis of the cd69 early activation antigen by two monoclonal antibodies directed to different epitopes. Molecular Immunology, 28(1–2):159–168, January 1991. URL: http://dx.doi.org/10.1016/0161-5890(91)90100-x, doi:10.1016/0161-5890(91)90100-x. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0161-5890(91)90100-x)